stock market performance


Data show that Silicon Valley darlings once again captured the interest of stock fund managers looking to cash in on the sector’s growth and dreams in the fourth quarter of 2016.

In a ranking of the 20 S&P 500 stocks that U.S. funds managing more than $1 million bought the most, tech companies took eight spots: Microsoft (NASDAQ:MSFT), Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOGL), Facebook (NASDAQ:FB), Amazon (NASDAQ:AMZN), Cisco (NASDAQ:CSCO), Alphabet (NASDAQ:GOOG) and Intel (NASDAQ:INTC). Microsoft and Apple also saw the most buying in the S&P 500, according to data compiled by GuruFocus.


The results show U.S. investment fund managers packing into a market sector that already sprinted through last year, gaining 23.5% in 2016 versus 9.54% in the S&P 500. So far, it has not broken a sweat going into 2017, rising 29.49% year to date versus 5.58% in the S&P 500. Only one sector has outperformed it, financials, which rose 44.90% year to date on the back of investor optimism in future tax cuts and interest rate hikes.

stock market performance: Novo Nordisk A/S(NVO)

Advisors’ Opinion:

  • [By Brian Orelli]

    Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.


    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.


    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:

  • [By Paul Ausick]

    Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.

stock market performance: Sonoco Products Company(SON)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Deutsche Bank’s Debbie Jones and team contend that Sonoco’s (SON) sale of its plastic-container business to Australia’s Amcor is a sign that M&A is in the offing. They explain why:

    Sonoco announced (9/1) that it is selling its Rigid Plastics Blow Molding operations to Amcor (AMC.AU) for $280M. The transaction price represents a multiple of ~8.0x LTM EBITDA. The business had annual sales of ~$210M and consisted of six production sites in the US and one in Canada. Blow molding operations represented ~10% of Sonocos Consumer Packaging segment sales and EBITDA. The transaction is expected to close in Q4. We expect the proceeds to be used to for M&A focused in flexible packaging, thermoforming and temperature-assured packaging.


    We dont believe Sonoco considered its blow molding operations essential to its growth strategy. This standalone business is also more capital intensive compared to some of its other plastic packaging businesses and SON held a small position in the overall market. Ultimately, the company decided it wants to focus its capital in higher growth platforms. We do not expect the divestment to reduce resin buying scale for Sonoco’s remaining assets given different resin buying. Note that with the divestiture of blow molding and the Canton closures plant (divested in Feb. 2015), this makes the ~$100M reels business the last standalone business in the portfolio, but we do not expect this to be divested in the near-term unless cash is needed for much larger M&A.


    Shares of Sonoco have gained 1.3% to $52.49 at 2:12 p.m. today.

     

stock market performance: AXT Inc(AXTI)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

stock market performance: SPDR Wells Fargo Preferred Stock ETF (PSK)


Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI holds five other SSgA fixed income ETFs, including the SPDR Wells Fargo Preferred Stock ETF (NYSE: PSK). PSK is DWFI's largest holding at a weight of 25.2 percent. DWFI's second-largest holding is an allocation of almost 25 percent to the SPDR Nuveen Barclays Municipal Bond ETF (NYSE: TFI).

stock market performance: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

Leave a Reply

Your email address will not be published. Required fields are marked *